Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ampelopsis brevipedunculata extract is a botanical preparation derived from the plant Ampelopsis brevipedunculata (commonly known as Amur peppervine or porcelain berry), traditionally used in East Asian medicine. The extract contains various bioactive compounds including triterpenes, flavonoids, tannins, and carbohydrates[10]. It has demonstrated anti-inflammatory and anti-hepatotoxic activities in preclinical studies. Mechanistically, the ethanol extract inhibits inflammatory signaling pathways such as JAK2/STAT3 and NF-κB by reducing phosphorylation of STAT3, JAK2, ERK proteins[1][2]. It also suppresses cytokine production (e.g., TNF-α, IL-6) and immune cell infiltration in models of atopic dermatitis[1][3], reduces serum IgE/histamine levels[3], and inhibits osteoclastogenesis by downregulating genes involved in bone resorption (e.g., OSCAR, TRAP)[5]. The hepatoprotective effect is attributed to antioxidant activity against iron-induced hepatocyte injury[8]. Its primary indications under investigation are skin inflammation (atopic dermatitis), liver disorders/hepatoprotection, and bone loss/osteoporosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ampelopsis brevipedunculata extract.